- Product NamePioglitazone hydrochloride
- Brief DescriptionInhibitors
- Purification99.50%
- Biological ActivityPioglitazone hydrochloride can increase both insulin-stimulated glucose uptake in peripheral tissues and insulin sensitivity in hepatic and adipose tissue. It is treated for hyperglycemia and Type 2 diabetes (T2D). Pioglitazone needs insulin as a co-factor for PPAR agonism so it is not effect when being treated to late stages of T2D with developed insulinopenia. In clinical trials, 15mg pioglitazone produces significant improvements in HbA1c and fasting plasma glucose (FPG).
- Target NamePPAR agonist
- CAS No. 112529-15-4
- Calculated MW 392.9
- Formulation C19H20N2O3SHCl
- Storage 3 years -20˚C powder;2 years -80˚C in solvent;
